IntrinsicIntrinsic
← All summaries

Cingulate Inc.

CINGW
Financials & Chart →

Business Summary

Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform technology . The company's core business model revolves around developing once-daily, multi-dose tablets designed to improve patient lives by addressing burdensome daily dosing regimens and suboptimal treatment outcomes for frequently diagnosed conditions . The PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) to enable drug substance release at specific, pre-defined time intervals . The primary customer segments targeted are patients suffering from Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety . The company currently generates no revenue from product sales .

Cingulate is targeting the ADHD treatment market, which had an estimated U.S. market size of approximately 100 million annual prescriptions of stimulants as of September 2025 . The average branded long-acting stimulant wholesale acquisition cost (WAC) is $495 per prescription . The company estimates that a 1% market share capture in this market would represent approximately $250 million to $300 million in annual revenue, less rebates and discounts . Stimulants are the most commonly prescribed class of medications for ADHD, accounting for approximately 90% of all ADHD medication prescriptions in the U.S. during the year ended September 30, 2025 . The company believes there is a significant unmet need for true once-daily ADHD stimulant medications with lasting duration . For anxiety, the U.S. sales of buspirone accounted for over $1 billion in 2025 within the $15.2 billion anxiety and depression market .

The company's pipeline includes two proprietary, first-line stimulant medications for ADHD: CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) . Both are designed to provide immediate onset of action (within 30 minutes), entire 'active-day' duration, eliminate the need for 'booster/recovery' doses, minimize rebound/crash symptoms, and offer favorable tolerability . CTx-1301 is a trimodal extended-release tablet providing three distinct releases of dexmethylphenidate hydrochloride: an initial immediate-release dose (35% of total daily dose) within five to six minutes, a first delayed, sustained release (45% of total daily dose) three hours after administration, and a second delayed, immediate release (20% of total daily dose) seven hours after administration . CTx-1301 is expected to be available in eight dosage strengths ranging from 6.25mg to 50mg . CTx-1302 is also a trimodal extended-release tablet with a release profile of 45% immediate release, 35% first delayed release, and 20% second delayed release . CTx-1302 is also expected to be available in eight dosage strengths from 6.25mg to 50mg .

Cingulate is also developing CTx-2103 (buspirone) for the treatment of anxiety, designed as a true, once-daily administration using the PTR platform . Buspirone is a non-benzodiazepine anxiolytic with a decreased side-effect profile and no associated risk of physical dependence or withdrawal . The formulation study for CTx-2103 demonstrated a triple release of buspirone .

For the year ended December 31, 2025, Cingulate reported net losses of $22.4 million , compared to $16.6 million for the year ended December 31, 2024 . The accumulated deficit as of December 31, 2025, was $132.4 million . Research and development expenses were $12,986,000 in 2025, an increase from $10,131,000 in 2024 . General and administrative expenses were $10,107,000 in 2025, up from $6,450,000 in 2024 . The company had no revenue in either period .

During 2025, the company sold 785,784 shares of common stock under an At-the-Market (ATM) Agreement for net proceeds of $3,574,574 . Under the Original LP Purchase Agreement, 897,415 shares of common stock were sold for net proceeds of $3,513,236, and this agreement expired as of June 30, 2025 . A second purchase agreement, the 2025 LP Purchase Agreement, was entered into on July 21, 2025, under which 852,948 shares of common stock were sold for net proceeds of $3,238,007 in 2025 . In December 2024, the company issued an unsecured promissory note (the 2024 Note) for $5,480,000, receiving $5,000,000 in cash . During 2025, $4,675,000 in principal of the 2024 Note was exchanged for 1,167,300 shares of common stock . On November 7, 2025, an unsecured promissory note (the 2025 Note) for $6,570,000 was issued to Avondale Capital, LLC, for a cash purchase price of $6,000,000 .

Cingulate submitted a New Drug Application (NDA) for CTx-1301 to the FDA on July 31, 2025 . The FDA accepted the NDA for review on September 29, 2025, and assigned a PDUFA target action date of May 31, 2026 . In February 2026, the FDA conducted a pre-approval inspection of the CDMO's Gainesville, GA facility, which resulted in a Form 483 with three observations . The company also entered into a commercial supply agreement with Bend Bioscience (formerly Societal CDMO, Inc.) effective August 27, 2025, for the manufacture of CTx-1301 . Joint commercialization agreements for CTx-1301 were established with Indegene, Inc. in May 2025 and IQVIA Inc. in November 2025 .

Business Outlook

Cingulate expects to continue incurring significant expenses and operating losses in the near term as it seeks regulatory approval for CTx-1301, continues research and development activities for existing and new product candidates, primarily CTx-1301, continues manufacturing activities, primarily for CTx-1301, advances commercialization efforts for CTx-1301, and operates as a public company . The company believes its cash on hand will satisfy capital needs late into the fourth quarter of 2026 under its current business plan, which primarily includes activities related to seeking regulatory approval for CTx-1301 and pre-commercialization efforts for CTx-1301 . Additional capital will be required to advance other programs .

A major growth area for Cingulate is the potential commercialization of CTx-1301 for ADHD. The NDA for CTx-1301 was submitted to the FDA on July 31, 2025, and accepted for review on September 29, 2025, with a PDUFA target action date of May 31, 2026 . If approved, CTx-1301 is expected to be the first true once-daily dexmethylphenidate tablet for ADHD, offering rapid onset within 30 minutes and entire 'active-day' efficacy . The company plans to commercialize CTx-1301 in the United States through partnerships with Indegene, Inc. for marketing, market access and pricing, commercial operations, and omnichannel services, and with IQVIA Inc. for field sales and national account management . The ADHD treatment market is substantial, with approximately 100 million annual prescriptions of stimulants in the U.S. as of September 2025, and a 1% market share could represent $250 million to $300 million in annual revenue .

Another growth vector is the development of CTx-2103 for anxiety. The company received FDA feedback in Q4 2023 regarding the regulatory pathway for CTx-2103, indicating it may be eligible for approval under the 505(b)(2) pathway, which typically requires less time and resources than a full NDA . CTx-2103 is designed as a once-daily, modified-release buspirone tablet, aiming to differentiate from standard multi-dose options . The U.S. anxiety and depression market was $15.2 billion in 2025, with buspirone sales exceeding $1 billion . Additional capital resources will be required to continue the development of CTx-2103 .

The company also plans to advance the development of CTx-1302 (dextroamphetamine) for ADHD, pending additional capital resources . CTx-1302 is envisioned as a true once-daily dextroamphetamine tablet with rapid onset and entire active-day efficacy . The clinical plan for CTx-1302 includes Phase 1/2 bioavailability studies (approximately 100 patients) and pivotal Phase 3 clinical trials (approximately 500 patients), with the timing dependent on capital availability .

Operationally, the company expects general and administrative expenses to increase due to growing operations, including potential commercialization of CTx-1301, and costs associated with being a public company . Research and development expenses are also expected to increase as product candidates advance to later stages of clinical development, which generally have higher costs due to increased size and duration of trials . The company relies on CoreRx, Inc. (dba Bend Bioscience) as its CDMO for manufacturing clinical, registration, and commercial batches of CTx-1301 at a dedicated suite in its Gainesville, GA facility, outfitted with company-supplied equipment . The Manufacturing Agreement with Bend Bioscience is effective until August 2028 and renews automatically for one-year periods unless terminated .

For capital allocation, the company intends to retain any future earnings to finance the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future . The company's compensation program includes granting stock options to attract, retain, and incentivize employees . As of March 18, 2026, the company had approximately $13.3 million of availability under the 2025 LP Purchase Agreement .

The company faces structural headwinds and execution risks, including the need to raise significant additional capital to support planned development and commercialization activities, as current cash is estimated to satisfy needs only late into the fourth quarter of 2026 . There is no assurance that additional funding will be available on acceptable terms, or at all . The 2025 Note Purchase Agreement with Avondale Capital, LLC, for $6,570,000, contains restrictive covenants and adjustments in the event of default, including the right for the lender to increase the outstanding balance by 15% for a "Major Trigger Event" or 5% for a "Minor Trigger Event" (each up to three times) and declare amounts immediately due and payable . The lender may also redeem up to $660,000 per month of the 2025 Note starting May 7, 2026, with deferral options incurring a 1% increase in outstanding balance . The FDA's pre-approval inspection of the CDMO facility in February 2026 resulted in a Form 483 with three observations, which could delay or prevent CTx-1301 approval . Government initiatives like the "Make America Healthy Again Commission" could propose new guidelines impacting approval, labeling, marketing, and prescription of ADHD and anxiety drugs, potentially leading to stricter regulatory policies, increased costs, or reduced market access .

Risk Factors

Cingulate faces substantial risks, including its limited operating history and recurring operating losses, with an accumulated deficit of approximately $132.4 million as of December 31, 2025 , raising substantial doubt about its ability to continue as a going concern . The company is heavily dependent on the successful development and regulatory approval of CTx-1301, for which the FDA issued a Form 483 with three observations during a pre-approval inspection in February 2026 , potentially delaying or preventing approval by the PDUFA target action date of May 31, 2026 . Significant additional capital is required to continue operations, with current cash projected to last only until late Q4 2026 , and failure to raise funds could lead to bankruptcy or loss of securityholder investment . The 2025 Note Purchase Agreement with Avondale Capital, LLC, for $6,570,000 , includes restrictive covenants, potential interest rate increases to 22% per annum upon default , and monthly redemption rights of up to $660,000 starting May 7, 2026 , which could strain liquidity. The company's reliance on a single CDMO for manufacturing CTx-1301 and third parties for clinical trials and commercialization exposes it to supply chain disruptions, manufacturing failures, and non-performance risks. Intellectual property protection is critical, but patents may be challenged, narrowed, or invalidated, and costly litigation is a constant threat, especially given the 505(b)(2) pathway which invites patent infringement suits . Regulatory changes, such as those from the "Make America Healthy Again Commission," could impose stricter requirements or limit the market for ADHD and anxiety treatments .

Management Priorities

Management emphasizes its commitment to leveraging the proprietary Precision Timed Release (PTR) drug delivery platform to develop next-generation pharmaceutical products that improve patient lives by addressing burdensome daily dosing regimens and suboptimal treatment outcomes . A key strategic priority is obtaining regulatory approval for CTx-1301 for ADHD, for which an NDA was submitted to the FDA on July 31, 2025, and accepted for review with a PDUFA target action date of May 31, 2026 . Management is actively engaged with the FDA, having responded to all information requests, primarily related to CMC, and is working with its CDMO to address the three observations from the February 2026 pre-approval inspection . Another strategic focus is the successful commercialization of CTx-1301, if approved, through partnerships with Indegene for marketing and commercial operations, and IQVIA for field sales and national account management . The company also prioritizes advancing clinical trials for CTx-2103 for anxiety, aiming for a once-daily formulation under the 505(b)(2) pathway, and advancing CTx-1302 for ADHD, both contingent on securing additional capital resources . Management also intends to maximize the PTR platform's potential to develop additional product candidates in new indications with significant unmet medical need and billion-dollar revenue potential, while continuously evaluating in-licensing or out-licensing opportunities and strengthening its intellectual property portfolio .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Revenue
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Overview
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — ADHD Overview and Drawbacks of Current Therapies
  7. [7] Item 1, Business — Overview
  8. [8] Item 1, Business — Overview
  9. [9] Item 1, Business — Our Lead Candidate CTx-1301: Dexmethylphenidate for the Treatment of ADHD in 6 Years and Older
  10. [10] Item 1, Business — Our Lead Candidate CTx-1301: Dexmethylphenidate for the Treatment of ADHD in 6 Years and Older
  11. [11] Item 1, Business — CTx-1302: Dextroamphetamine for the treatment of ADHD in 6 years and older
  12. [12] Item 1, Business — CTx-1302: Dextroamphetamine for the treatment of ADHD in 6 years and older
  13. [13] Item 1, Business — Overview
  14. [14] Item 1, Business — CTx-2103: Buspirone product candidate for the treatment of anxiety related disorders
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Overview
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Revenue
  20. [20] Item 7, MD&A — Securities Issuances - ATM Agreement
  21. [21] Item 7, MD&A — Securities Issuances - Equity Line of Credit
  22. [22] Item 7, MD&A — Securities Issuances - Equity Line of Credit
  23. [23] Item 7, MD&A — Securities Issuances - Debt Issuance
  24. [24] Item 7, MD&A — Securities Issuances - Debt Issuance
  25. [25] Item 7, MD&A — Securities Issuances - Debt Issuance
  26. [26] Item 1, Business — CTx-1301
  27. [27] Item 1, Business — CTx-1301
  28. [28] Item 1, Business — Our Strategy
  29. [29] Item 1, Business — Manufacturing
  30. [30] Item 1, Business — CTx-1301
  31. [31] Item 7, MD&A — Overview
  32. [32] Item 7, MD&A — Overview
  33. [33] Item 1, Business — Our Strategy
  34. [34] Item 1, Business — Our Lead Candidate CTx-1301: Dexmethylphenidate for the Treatment of ADHD in 6 Years and Older
  35. [35] Item 1, Business — Commercialization
  36. [36] Item 1, Business — Overview
  37. [37] Item 1, Business — CTx-2103
  38. [38] Item 1, Business — CTx-2103
  39. [39] Item 1, Business — Overview
  40. [40] Item 1, Business — CTx-2103
  41. [41] Item 1, Business — CTx-1302
  42. [42] Item 1, Business — CTx-1302: Dextroamphetamine for the treatment of ADHD in 6 years and older
  43. [43] Item 1, Business — Our CTx-1302 Clinical Development Program
  44. [44] Item 7, MD&A — General and Administrative Expenses
  45. [45] Item 7, MD&A — Research and Development Expenses
  46. [46] Item 1, Business — Manufacturing
  47. [47] Item 1, Business — Material Agreements - Master Services Agreement with CoreRx, Inc. (dba Bend Bioscience)(fka Societal CDMO)
  48. [48] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividend Policy
  49. [49] Item 1, Business — Human Capital Resources
  50. [50] Item 7, MD&A — Securities Issuances - Equity Line of Credit
  51. [51] Item 1A, Risk Factors — Risks Related to Our Financial Position and Need for Capital
  52. [52] Item 1A, Risk Factors — Risks Related to Our Financial Position and Need for Capital
  53. [53] Item 1A, Risk Factors — The note purchase agreement and note issued by us in November 2025 contain restrictive covenants and adjustments in the event we default on the Note that may limit our operating flexibility and impact our operations.
  54. [54] Item 1A, Risk Factors — The note purchase agreement and note issued by us in November 2025 contain restrictive covenants and adjustments in the event we default on the Note that may limit our operating flexibility and impact our operations.
  55. [55] Item 1A, Risk Factors — We depend heavily on the success of CTx-1301. If we are unable to secure approval of CTx-1301, we will never be able to generate revenues from CTx-1301, and our ability to create stockholder value will be severely limited.
  56. [56] Item 1A, Risk Factors — Government initiatives such as the Make America Healthy Again Commission could affect the development and approval of our product candidates
  57. [57] Item 7, MD&A — Overview
  58. [58] Item 1A, Risk Factors — The report of our independent registered public accounting firm for the fiscal years ended December 31, 2025 and 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
  59. [59] Item 1A, Risk Factors — We depend heavily on the success of CTx-1301. If we are unable to secure approval of CTx-1301, we will never be able to generate revenues from CTx-1301, and our ability to create stockholder value will be severely limited.
  60. [60] Item 1A, Risk Factors — We depend heavily on the success of CTx-1301. If we are unable to secure approval of CTx-1301, we will never be able to generate revenues from CTx-1301, and our ability to create stockholder value will be severely limited.
  61. [61] Item 7, MD&A — Overview
  62. [62] Item 1A, Risk Factors — We will need to raise significant additional capital to continue operations. If we are unable to raise capital, we could be required to seek bankruptcy protection or other alternatives that would likely result in our securityholders losing some or all of their investment in us.
  63. [63] Item 7, MD&A — Securities Issuances - Debt Issuance
  64. [64] Item 1A, Risk Factors — The note purchase agreement and note issued by us in November 2025 contain restrictive covenants and adjustments in the event we default on the Note that may limit our operating flexibility and impact our operations.
  65. [65] Item 1A, Risk Factors — The note purchase agreement and note issued by us in November 2025 contain restrictive covenants and adjustments in the event we default on the Note that may limit our operating flexibility and impact our operations.
  66. [66] Item 1A, Risk Factors — We rely on third-parties, many of whom are our single source for services, products and/or supplies, over whom we have limited control. Should the cost, delivery and/or quality of services, products or supplies provided by these third-parties vary to our disadvantage, our business operations could suffer significant harm.
  67. [67] Item 1A, Risk Factors — We will rely on third parties to commercialize our product candidates and we may rely on third parties to perform many essential services for any products that we commercialize, including distribution, customer service, accounts receivable management, cash collection and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our product candidates will be significantly impacted and we may be subject to regulatory sanctions.
  68. [68] Item 1A, Risk Factors — If our intellectual property related to our products or product candidates is not adequate, we may not be able to compete effectively in our market.
  69. [69] Item 1A, Risk Factors — Government initiatives such as the Make America Healthy Again Commission could affect the development and approval of our product candidates
  70. [70] Item 1, Business — Our Strategy
  71. [71] Item 1, Business — Our Strategy
  72. [72] Item 1, Business — Our Strategy
  73. [73] Item 1, Business — Our Strategy
  74. [74] Item 1, Business — Our Strategy
  75. [75] Item 1, Business — Our Strategy

Analysis on 5/20/2026